Drug Trial Radar · NCT00113607
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
672
Actual
Start
Apr 2005
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- PharmaMar
- First posted
- Jun 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
TrabectedinDrug
Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
DOXILDrug
Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
DexamethasoneDrug
Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS): Independent Radiologist ReviewTime frame: From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years
Locations
111 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Tucson, Arizona
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Orange, California
Site not named
Englewood, Colorado
Site not named
Stamford, Connecticut
Site not named
Tampa, Florida
Site not named
Coeur d'Alene, Idaho
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Boston, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
Morristown, New Jersey
Site not named
New York, New York
Site not named
Charlotte, North Carolina
Site not named
Greenville, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Site not named
Toledo, Ohio
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Chattanooga, Tennessee
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Galveston, Texas
Site not named
Buenos Aires, Argentina
Site not named
Mendoza, Argentina
Site not named
Sante Fe, Argentina
Site not named
Adelaide, Australia
Site not named
Bentleigh, Australia
Site not named
Douglas, Australia
Site not named
St Leonards, Australia
Site not named
Toorak Gardens, Australia
Site not named
Edegem, Belgium
Site not named
Hasselt, Belgium
Site not named
Leuven, Belgium
Site not named
Wilrijk, Belgium
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.